Evidence map›Paper›PMID 31461933›Full record

ArticleMolecules (Basel, Switzerland)2019

Kurarinone from

Sakiko Nishikawa, Yuka Itoh, Muneshige Tokugawa, Yasumichi Inoue, Ken-Ichi Nakashima, Yuka Hori, Chiharu Miyajima, Kou Yoshida, Daisuke Morishita, Nobumichi Ohoka and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Kurarinone: From chemistry to pharmacological values-A review.Iranian journal of basic medical sciences · 2026
    Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Sakiko NishikawaDepartment of Cell Signaling, Graduate School of Pharmaceutical Sciences and Nagoya City University, Nagoya 467-8603, Japan.
Yuka ItohDepartment of Cell Signaling, Graduate School of Pharmaceutical Sciences and Nagoya City University, Nagoya 467-8603, Japan.
Muneshige TokugawaDepartment of Cell Signaling, Graduate School of Pharmaceutical Sciences and Nagoya City University, Nagoya 467-8603, Japan.
Yasumichi InoueDepartment of Cell Signaling, Graduate School of Pharmaceutical Sciences and Nagoya City University, Nagoya 467-8603, Japan. yainoue@phar.nagoya-cu.ac.jp.ORCID 0000-0002-1667-1381
Ken-Ichi NakashimaLaboratory of Medicinal Resources, School of Pharmacy, Aichi Gakuin University, Nagoya 464-8650, Japan.ORCID 0000-0002-3050-9903
Yuka HoriDepartment of Cell Signaling, Graduate School of Pharmaceutical Sciences and Nagoya City University, Nagoya 467-8603, Japan.
Chiharu MiyajimaDepartment of Cell Signaling, Graduate School of Pharmaceutical Sciences and Nagoya City University, Nagoya 467-8603, Japan.
Kou YoshidaDepartment of Cell Signaling, Graduate School of Pharmaceutical Sciences and Nagoya City University, Nagoya 467-8603, Japan.
Daisuke MorishitaDepartment of Cell Signaling, Graduate School of Pharmaceutical Sciences and Nagoya City University, Nagoya 467-8603, Japan.
Nobumichi OhokaDivision of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, Kanagawa 210-9501, Japan.
Makoto InoueLaboratory of Medicinal Resources, School of Pharmacy, Aichi Gakuin University, Nagoya 464-8650, Japan.
Hajime MizukamiDepartment of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya 467-8603, Japan.
Toshiaki MakinoDepartment of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya 467-8603, Japan.ORCID 0000-0002-2524-8745
Hidetoshi HayashiDepartment of Cell Signaling, Graduate School of Pharmaceutical Sciences and Nagoya City University, Nagoya 467-8603, Japan. hhayashi@phar.nagoya-cu.ac.jp.
Nagoya City University · JPAichi Gakuin University · JPNational Institute of Health Sciences · JP

Funding

Japan Society for the Promotion of Science 15K07936Japan Society for the Promotion of Science 15K07937Japan Society for the Promotion of Science 18K06660Japan Society for the Promotion of Science 18K16081
6 · The paper itself

Abstract

In response to cellular stresses, activating transcriptional factor 4 (ATF4) regulates the expression of both stress-relieving genes and apoptosis-inducing genes, eliciting cell fate determination. Since pharmacological activation of ATF4 exerts potent anti-tumor effects, modulators of ATF4 activation may have potential in cancer therapy. We herein attempted to identify small molecules that activate ATF4. A cell-based screening to monitor

Indexed as

Activating Transcription Factor 4Cell Cycle ProteinsCell Line, TumorCell ProliferationCell SurvivalDrug Screening Assays, AntitumoreIF-2 KinaseFlavonoidsGene Expression Regulation, NeoplasticHEK293 CellsHeLa CellsHumansPhosphorylationPromoter Regions, GeneticProtein Serine-Threonine KinasesRepressor ProteinsActivating Transcription Factor 4ATF4 protein, humanCell Cycle ProteinsEIF2AK3 protein, humaneIF-2 KinaseFlavonoidskurarinoneProtein Serine-Threonine KinasesRepressor ProteinsTRIB3 protein, humanATF4cancerISRkurarinonePERKSophora flavescensTRB3

Identifiers

PMID31461933
PMCPMC6749437
OpenAlexW2970681224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.